New & Notable
Drug manufacturing deals move to Europe despite pharma tariffs
Last year marked the sharpest decline in U.S. contract manufacturing deals for FDA-approved drugs in half a decade, despite Trump's push for domestic onshoring, GlobalData finds.
Trump revives pharma tariffs with 100% charges, but leaves loopholes
“Section 232” national security levies won’t apply to a wide array of drugs, meaning the “overall threat to the sector should be low,” according to one analyst.
— BioPharma Dive
Novo claims edge over Lilly's newly approved GLP-1 pill in cross study
Novo Nordisk is claiming the upper hand over Eli Lilly in the oral weight-loss drug market, saying its oral Wegovy topped Lilly's recently approved GLP-1 pill in a cross-trial comparison.
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.
— BioPharma DiveBlackstone closes $6.3B fund for life sciences investing
— BioPharma DiveWave crashes on obesity drug update; Kodiak’s reboot pays dividends
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Lilly's triple-G agonist shows unique promise in late-stage diabetes trial
Eli Lilly's experimental triple hormone agonist, retatrutide, helped patients with type 2 diabetes lower blood sugar by up to 2% and lose up to 16.8% of their weight in a phase 3 study.
-
Roche's new NVIDIA deal locks in the industry's 'largest hybrid-cloud AI factory'
Roche is expanding its global AI infrastructure to deploy a large-scale AI factory powered by NVIDIA's latest-generation accelerated computing stack to speed up drug and diagnostics development.
-
Structure's GLP-1 pill shows 'injectable-like efficacy' in a mid-stage obesity study
Structure Therapeutics' GLP-1 pill, aleniglipron, triggered up to 16.2% continued weight loss in a phase 2 obesity trial, reaffirming its "best in class" potential.
-
Lilly warns of impurities in compounded tirzepatide containing B12
Eli Lilly says compounded tirzepatide products mixed with vitamin B12 have been found to form impurities that could pose safety risks.
-
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial
Regeneron's dual GLP-1/GIP obesity shot, licensed from Hansoh Pharma, achieved phase 3 weight-loss results that come close to those of Lilly's Zepbound, but with better GI tolerability.
-
Roche, Zealand tout the tolerability of their amylin obesity drug
The Roche–Zealand amylin obesity drug, petrelintide, delivered up to 10.7% weight loss in a phase 2 obesity trial with a "placebo-like tolerability" profile, the companies say.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.